Evidence map›Paper›PMID 31302628›Full record

ArticleThe British journal of ophthalmology2020

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol.

Tiezhu Lin, Kunny C Dans, Ilkay Kilic Muftuoglu, Amit Meshi, Manuel J Amador-Patarroyo, Lingyun Cheng, William R Freeman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Trial
  3. Long-term remission and incidence of recurrence of neovascularization in intravitreal injection treated exudative age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 5 countries.

Tiezhu LinOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Kunny C DansOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Ilkay Kilic MuftuogluOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Amit MeshiOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Manuel J Amador-PatarroyoOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
Lingyun ChengOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA.
William R FreemanOphthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California, USA wrfreeman@ucsd.edu.ORCID 0000-0001-6382-1218
University of California San Diego · USRabin Medical Center · IL

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
NEI NIH HHS P30 EY022589
6 · The paper itself

Abstract

aimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.

methodsThis was a retrospective case-control study of a consecutive series of patients with nAMD treated with a PRN antivascular endothelial growth factor (anti-VEGF) drug regimen. ER was defined as the absence of haemorrhage, intraretinal/subretinal fluid on optical coherence tomography and leakage on fluorescein angiography for 52 weeks after cessation of anti-VEGF therapy. Matching patients with nAMD who did not achieve ER were included as control group. Cox regression analysis was fitted to identify predictors of time to achieve ER and time to recurrence. A logistic regression analysis of baseline characteristics was used to identify predictors of achieving ER.

resultsOf 830 eyes treated with anti-VEGF monotherapy, 77 (9.2%) eyes achieved ER during a median follow-up of 236 weeks (range 70-525 weeks). Cox regression analysis showed that ER was achieved earlier in eyes with isolated intraretinal fluid (HR, 2.05; 95% CI 1.929 to 4.520; p=0.045) at presentation. Logistic regression analysis showed that type 3 choroidal neovascularisation (OR, 0.090; 95% CI 0.021 to 0.382; p=0.001), thinner choroid (OR, 0.993; 95% CI 0.988 to 0.998; p=0.004) and absence of macular atrophy (OR, 0.233; 95% CI 0.065 to 0.839; p=0.026) at baseline increased the likelihood of achieving ER.

conclusionER is achievable in 9.2% of patients under PRN therapy for nAMD. At presentation with nAMD, anatomical features on retinal imaging may predict the likelihood of achieving ER and a shorter time to achieve ER.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsCase-Control StudiesChoroidal NeovascularizationDrug Administration ScheduleFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsKaplan-Meier EstimateMaleMiddle AgedPrognosisRecurrenceAngiogenesis InhibitorsVascular Endothelial Growth Factor AVEGFA protein, humanimagingmaculaneovascularisationretinatreatment medical

Identifiers

PMID31302628
PMCPMC6922015
OpenAlexW2962279257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.